Retatrutide is a monopeptide that binds to fatty diacids and has agonistic effects on glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon (GCG) receptors.

Retatrutide powder uses a chemical combination of GLP-1R/GIP/GCGR triple G.
Retatrutide is based on the GLP-1/GI dual receptor agonist Tirzepatide and achieves triple agonistic effects through a hybrid GlucagonGcg-related structure.
Compared with tilpotide, the activity of the peptide chain on GIP and glucagon receptors is enhanced. In addition, a binary fatty acid side chain that is exactly the same as tilpotide is introduced to extend the action time in the body.

Related products: Tirzepatide, Semaglutide Powder

From the analysis of the administration routes, administration cycles, and targets of GLP-1RA drugs on the market, it was found that the development trend of GLP-1RA drugs has evolved from long-acting to short-acting, from injection to oral administration, and from single-targeting to dual-targeting /multi-target transition.

Retatrutide

Product name	Retatrutide
CAS NO	2381089-83-2
Sequence	Tyr- {Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile- { α -Me-Leu}-Leu-Asp-Lys- {diacid-C20-gamma-Glu-(AEEA)-Lys}- Ala-Gln- {Aib}-Ala-Ph e-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro -Pro-Ser-NH2
Molecular Formula	C221H342N46O68
Molecular Weight	4731.33
Quantity	200g
Store at	Keep in dark and cool dry place

Items	Standards	Results
Appearance	White to off-white powder	Complies
Identity by MS	Theoretical MW:4731.33	Complies
Purity (HPLC)	Not less than 98.0%	99.16%
Sodium salt	Not more than 5.0%	0.61%
Water Content (K.F)	Not more than 7.0%	3.58%
Peptide Content	Not less than 85.0%	Complies
Conclusion	Conforms to standard	Complies

Retatrutide

The highest dose of retarglutide reduced obese patients' weight by 24% over 48 weeks.
Retalglutide is currently the GLP-1/GIP/GCG triple receptor agonist drug with the highest weight loss effect.
In addition to this, the drug may also be used to treat non-alcoholic fatty liver disease.

The side effects of retarglutide are dose-proportional and primarily gastrointestinal, with nausea occurring in 45% to 60% of participants at higher doses.

Retatrutide

Retatrutide powder can be used for R&D.

Reference

[1]. The Lancet. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.

[2]. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971-984.

Retatrutide